To view the Industry & Satellite CME Symposia schedule, please select the destination that is closest to your time zone and then click on the arrows below to see more details for each session.
| Agenda | |
| Welcome, Introduction, Polling Questions
Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC Activity of ADCs in Clinical Trials for Lung Cancer Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC Audience Q&A, Panel Discussion |
| Agenda | |
| 10:30 SGT | Opening Remarks Masahiro Tsuboi |
| 10:35 SGT | Current Strategies for IO Therapy for Unresectable Stage III NSCLC Glenwood Goss |
| 10:45 SGT | Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC Suresh Senan |
| 10:55 SGT | Defining the Role of Immunotherapy in the Treatment of ES-SCLC Myung-Ju Ahn |
| 11:05 SGT | Emerging Biomarkers in SCLC Charles Rudin |
| 11:15 SGT | Panel Discussion / Q&A All |
| Agenda | |
| 11:45 SGT | Welcome and Introduction Tony Mok |
| 11:50 SGT | Evolving challenges for the treatment of advanced NSCLC Tony Mok |
| 12:00 SGT | Emerging ADC targets for the treatment of late-line NSCLC Pasi Jänne |
| 12:15 SGT | ADC therapies as targeted treatment options in patients with advanced NSCLC James Yang |
| 12:30 SGT | Interactive Q+A/Panel Discussion All |
| Agenda | |
| 13:00 SGT | Chair’s Welcome Koichi Goto |
| 13:04 SGT | Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC Koichi Goto |
| 13:10 SGT | Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC – Practical tips on optimising diagnostic capabilities in the clinic Herbert Loong |
| 13:22 SGT | The roles of the Oncologist and Pathologist in providing an actionable diagnosis – Discuss the role of the Tumour Board / MDT in implementing precision medicine Fernando López-Ríos |
| 13:34 SGT | Gaining consensus – An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\ Giuseppe Curigliano |
| 13:44 SGT | Panel discussion and Q&A All |
| 14:00 SGT | Symposium close Koichi Goto |
| Agenda | |
| 14:15 SGT | Welcome and Introductions Rina Hui |
| 14:15 SGT | Frontline Immunotherapy Treatment Options in mNSCLC Rina Hui |
| 14:30 SGT | Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer Roy Herbst |
| 14:45 SGT | Choosing Immunotherapy Alone or in Combination in 1L mNSCLC Corey Langer |
| 15:00 SGT | Q&A and Closing Remarks Rina Hui |
| Agenda | |
| 15:30 SGT | Welcome and introduction Yi-Long Wu |
| 15:30 SGT | Evolution of the NSCLC Treatment Landscape Yi-Long Wu |
| 15:40 SGT | Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET? Johan F. Vansteenkiste |
| 15:55 SGT | Panel discussion All |
| 15:07 SGT | Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target Yasushi Goto |
| 16:21 SGT | Q&A All |
| 16:29 SGT | Closing Yi-Long Wu |
| Agenda | |
| 16:45 SGT | The Past, Present and Future of Biomarker-driven Advanced NSCLC Ben Solomon, Shirish Gadgeel, Solange Peters |
| 17:15 SGT | Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer Ross Soo, Martin Reck, Solange Peters |
| Agenda | |
| 13:00 SGT | Welcome and introductions Tetsuya Mitsudomi |
| 13:05 SGT | A light at the end of the tunnel Hope for patients with EGFR Exon20 insertion mutations Byoung Chul Cho |
| 13:25 SGT | The dawn of a new era Novel treatments for patients with TKI resistant disease with common EGFR mutations Enriqueta Felip |
| 13:45 SGT | Live Q&A: From information to transformation Navigating the evidence with experience sharing in a live forum to improve patient care All |
| Agenda | |
| 13:00 SGT | Welcome and Introduction Seng Weng Wong |
| 13:05 SGT | Navigating Recent Clinical Data for ALK+ TKIs Thanyanan Reungwetwattana Selecting Treatment and Management of ALK+ NSCLC Nick Pavlakis The Importance of Managing CNS disease John Chang The future of ALK+ NSCLC Nir Peled |
| 13:45 SGT | Q&A All |
| 13:58 SGT | Summary, Thank you and Close Seng Weng Wong |
| Agenda | |
| 13:00 SGT | Welcome and Introductions Virginie Westeel, MD, PhD |
| 13:05 SGT | What is the role of IO in Non-metastatic NSCLC? Virginie Westeel, MD, PhD |
| 13:20 SGT | IO in the treatment of Metastatic NSCLC, where are we now? Julie Brahmer, MD, MSc |
| 13:35 SGT | Non-Metastatic and Metastatic NSCLC Q&A Virginie Westeel, MD, PhD Julie Brahmer, MD, MSc |
| 13:40 SGT | What is I-O’s impact on the treatment paradigm for Mesothelioma patients? Nicolas Girard, MD |
| 13:55 SGT | Mesothelioma Q&A and Closing Remarks Nicolas Girard, MD Virginie Westeel, MD, PhD |
| Agenda | |
| Introductions
Current biomarker landscape in NSCLC Current unmet need in KRAS G12C-mutated NSCLC Emerging novel targets for lung cancer |
| Agenda | |
| 13:00 SGT | Introduction David Gandara, MD |
| 13:05 SGT | Know How To Test Your Patients John Gosney, MD |
| 13:15 SGT | Know How To Sequence EGFR TKIs Barbara Melosky, MD, FRCP(C) |
| 13:25 SGT | Know Your Patients With Uncommon EGFR Mutations Satoru Miura, MD, PhD |
| 13:35 SGT | What’s Next For Treatment of Advanced Stage Squamous NSCLC David Gandara, MD |
| 13:45 SGT | Know What’s Next For Your Patients: Looking to the Future David Gandara, MD |
| 13:55 SGT | Closing David Gandara, MD |
| Agenda | |
| 13:00 SGT | Welcome, introduction, and interactive quiz Daniel S.W. Tan, MD, PhD |
| 13:05 SGT | When is the right time to use NGS-based liquid biopsy in advanced NSCLC? Herbert Ho Fung Loong, MD |
| 13:20 SGT | Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice Terufumi Kato, MD |
| 13:35 SGT | Enhancing immune checkpoint inhibition with bifunctional antibodies Daniel S.W. Tan, MD, PhD |
| 13:50 SGT | Quiz questions revisited and Q&A All |
| 13:59 SGT | Pearls for practice Daniel S.W. Tan, MD, PhD |
| Agenda | |
| 13:00 SGT | Welcome and introduction Edward Kim |
| 13:05 SGT | Presentation: Advances and challenges in EGFR-mutated NSCLC Edward Kim |
| 13:15 SGT | Panel discussion: The MDT approach to managing EGFR-mutated NSCLC Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp |
| 13:45 SGT | Audience Q&A Faculty and audience |
| Agenda | |
| 13:00 SGT | Opening Remarks Tony Mok |
| 13:03 SGT | Biomarker for Lung Cancer: Right Patient, Right Time, Right Test Tony Mok |
| 13:21 SGT | Biomarker Panel Testing: PCR panel vs NGS panel Koichi Goto |
| 13:39 SGT | Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC Caicun Zhou |
| 13:57 SGT | Closing Remarks Tony Mok |
| Agenda | |
| Welcome, Introduction, Polling Questions
Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC Activity of ADCs in Clinical Trials for Lung Cancer Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC Audience Q&A, Panel Discussion |
| Agenda | |
| 03:30 CET | Opening Remarks Masahiro Tsuboi |
| 03:35 CET | Current Strategies for IO Therapy for Unresectable Stage III NSCLC Glenwood Goss |
| 03:45 CET | Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC Suresh Senan |
| 03:55 CET | Defining the Role of Immunotherapy in the Treatment of ES-SCLC Myung-Ju Ahn |
| 04:05 CET | Emerging Biomarkers in SCLC Charles Rudin |
| 04:15 CET | Panel Discussion / Q&A All |
| Agenda | |
| 04:45 CET | Welcome and Introduction Tony Mok |
| 04:50 CET | Evolving challenges for the treatment of advanced NSCLC Tony Mok |
| 05:00 CET | Emerging ADC targets for the treatment of late-line NSCLC Pasi Jänne |
| 05:15 CET | ADC therapies as targeted treatment options in patients with advanced NSCLC James Yang |
| 05:30 CET | Interactive Q+A/Panel Discussion All |
| Agenda | |
| 06:00 CET | Chair’s Welcome Koichi Goto |
| 06:04 CET | Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC Koichi Goto |
| 06:10 CET | Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC – Practical tips on optimising diagnostic capabilities in the clinic Herbert Loong |
| 06:22 CET | The roles of the Oncologist and Pathologist in providing an actionable diagnosis – Discuss the role of the Tumour Board / MDT in implementing precision medicine Fernando López-Ríos |
| 06:34 CET | Gaining consensus – An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\ Giuseppe Curigliano |
| 06:44 CET | Panel discussion and Q&A All |
| 07:00 CET | Symposium close Koichi Goto |
| Agenda | |
| 07:15 CET | Welcome and Introductions Rina Hui |
| 07:15 CET | Frontline Immunotherapy Treatment Options in mNSCLC Rina Hui |
| 07:30 CET | Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer Roy Herbst |
| 07:45 CET | Choosing Immunotherapy Alone or in Combination in 1L mNSCLC Corey Langer |
| 08:00 CET | Q&A and Closing Remarks Rina Hui |
| Agenda | |
| 08:30 CET | Welcome and introduction Yi-Long Wu |
| 08:30 CET | Evolution of the NSCLC Treatment Landscape Yi-Long Wu |
| 08:40 CET | Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET? Johan F. Vansteenkiste |
| 08:55 CET | Panel discussion All |
| 09:07 CET | Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target Yasushi Goto |
| 09:21 CET | Q&A All |
| 09:29 CET | Closing Yi-Long Wu |
| Agenda | |
| 09:45 CET | The Past, Present and Future of Biomarker-driven Advanced NSCLC Ben Solomon, Shirish Gadgeel, Solange Peters |
| 10:15 CET | Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer Ross Soo, Martin Reck, Solange Peters |
| Agenda | |
| 06:00 CET | Welcome and introductions Tetsuya Mitsudomi |
| 06:05 CET | A light at the end of the tunnel Hope for patients with EGFR Exon20 insertion mutations Byoung Chul Cho |
| 06:25 CET | The dawn of a new era Novel treatments for patients with TKI resistant disease with common EGFR mutations Enriqueta Felip |
| 06:45 CET | Live Q&A: From information to transformation Navigating the evidence with experience sharing in a live forum to improve patient care All |
| Agenda | |
| 06:00 CET | Welcome and Introduction Seng Weng Wong |
| 06:05 CET | Navigating Recent Clinical Data for ALK+ TKIs Thanyanan ReungwetwattanaSelecting Treatment and Management of ALK+ NSCLC Nick Pavlakis The Importance of Managing CNS disease The future of ALK+ NSCLC |
| 06:45 CET | Q&A All |
| 06:58 CET | Summary, Thank you and Close Seng Weng Wong |
| Agenda | |
| 06:00 CET | Welcome and Introductions Virginie Westeel, MD, PhD |
| 06:05 CET | What is the role of IO in Non-metastatic NSCLC? Virginie Westeel, MD, PhD |
| 06:20 CET | IO in the treatment of Metastatic NSCLC, where are we now? Julie Brahmer, MD, MSc |
| 06:35 CET | Non-Metastatic and Metastatic NSCLC Q&A Virginie Westeel, MD, PhD Julie Brahmer, MD, MSc |
| 06:40 CET | What is I-O’s impact on the treatment paradigm for Mesothelioma patients? Nicolas Girard, MD |
| 06:55 CET | Mesothelioma Q&A and Closing Remarks Nicolas Girard, MD Virginie Westeel, MD, PhD |
| Agenda | |
| Introductions
Current biomarker landscape in NSCLC Current unmet need in KRAS G12C-mutated NSCLC Emerging novel targets for lung cancer |
| Agenda | |
| 06:00 CET | Introduction David Gandara, MD |
| 06:05 CET | Know How To Test Your Patients John Gosney, MD |
| 06:15 CET | Know How To Sequence EGFR TKIs Barbara Melosky, MD, FRCP(C) |
| 06:25 CET | Know Your Patients With Uncommon EGFR Mutations Satoru Miura, MD, PhD |
| 06:35 CET | What’s Next For Treatment of Advanced Stage Squamous NSCLC David Gandara, MD |
| 06:45 CET | Know What’s Next For Your Patients: Looking to the Future David Gandara, MD |
| 06:55 CET | Closing David Gandara, MD |
| Agenda | |
| 06:00 CET | Welcome, introduction, and interactive quiz Daniel S.W. Tan, MD, PhD |
| 06:05 CET | When is the right time to use NGS-based liquid biopsy in advanced NSCLC? Herbert Ho Fung Loong, MD |
| 06:20 CET | Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice Terufumi Kato, MD |
| 06:35 CET | Enhancing immune checkpoint inhibition with bifunctional antibodies Daniel S.W. Tan, MD, PhD |
| 06:50 CET | Quiz questions revisited and Q&A All |
| 06:59 CET | Pearls for practice Daniel S.W. Tan, MD, PhD |
| Agenda | |
| 06:00 CET | Welcome and introduction Edward Kim |
| 06:05 CET | Presentation: Advances and challenges in EGFR-mutated NSCLC Edward Kim |
| 06:15 CET | Panel discussion: The MDT approach to managing EGFR-mutated NSCLC Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp |
| 06:45 CET | Audience Q&A Faculty and audience |
Date: Sunday, January 31, 2021 | Time: 06:00 - 07:00 CET
| Agenda | |
| 06:00 CET | Opening Remarks Tony Mok |
| 06:03 CET | Biomarker for Lung Cancer: Right Patient, Right Time, Right Test Tony Mok |
| 06:21 CET | Biomarker Panel Testing: PCR panel vs NGS panel Koichi Goto |
| 06:39 CET | Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC Caicun Zhou |
| 06:57 CET | Closing Remarks Tony Mok |
| Agenda | |
| Welcome, Introduction, Polling Questions
Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC Activity of ADCs in Clinical Trials for Lung Cancer Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC Audience Q&A, Panel Discussion |
| Agenda | |
| 21:30 EST | Opening Remarks Masahiro Tsuboi |
| 21:35 EST | Current Strategies for IO Therapy for Unresectable Stage III NSCLC Glenwood Goss |
| 21:45 EST | Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC Suresh Senan |
| 21:55 EST | Defining the Role of Immunotherapy in the Treatment of ES-SCLC Myung-Ju Ahn |
| 22:05 EST | Emerging Biomarkers in SCLC Charles Rudin |
| 22:15 EST | Panel Discussion / Q&A All |
| Agenda | |
| 22:45 EST | Welcome and Introduction Tony Mok |
| 22:50 EST | Evolving challenges for the treatment of advanced NSCLC Tony Mok |
| 23:00 EST | Emerging ADC targets for the treatment of late-line NSCLC Pasi Jänne |
| 23:15 EST | ADC therapies as targeted treatment options in patients with advanced NSCLC James Yang |
| 23:30 EST | Interactive Q+A/Panel Discussion All |
| Agenda | |
| 00:00 EST | Chair’s Welcome Koichi Goto |
| 00:04 EST | Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC Koichi Goto |
| 00:10 EST | Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC – Practical tips on optimising diagnostic capabilities in the clinic Herbert Loong |
| 00:22 EST | The roles of the Oncologist and Pathologist in providing an actionable diagnosis – Discuss the role of the Tumour Board / MDT in implementing precision medicine Fernando López-Ríos |
| 00:34 EST | Gaining consensus – An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\ Giuseppe Curigliano |
| 00:44 EST | Panel discussion and Q&A All |
| 01:00 EST | Symposium close Koichi Goto |
| Agenda | |
| 01:15 EST | Welcome and Introductions Rina Hui |
| 01:15 EST | Frontline Immunotherapy Treatment Options in mNSCLC Rina Hui |
| 01:30 EST | Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer Roy Herbst |
| 01:45 EST | Choosing Immunotherapy Alone or in Combination in 1L mNSCLC Corey Langer |
| 02:00 EST | Q&A and Closing Remarks Rina Hui |
| Agenda | |
| 02:30 PST | Welcome and introduction Yi-Long Wu |
| 02:30 EST | Evolution of the NSCLC Treatment Landscape Yi-Long Wu |
| 02:40 EST | Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET? Johan F. Vansteenkiste |
| 02:55 EST | Panel discussion All |
| 03:07 EST | Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target Yasushi Goto |
| 03:21 EST | Q&A All |
| 03:29 EST | Closing Yi-Long Wu |
| Agenda | |
| 03:45 EST | The Past, Present and Future of Biomarker-driven Advanced NSCLC Ben Solomon, Shirish Gadgeel, Solange Peters |
| 04:15 EST | Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer Ross Soo, Martin Reck, Solange Peters |
| Agenda | |
| 00:00 EST | Welcome and introductions Tetsuya Mitsudomi |
| 00:05 EST | A light at the end of the tunnel Hope for patients with EGFR Exon20 insertion mutations Byoung Chul Cho |
| 00:25 EST | The dawn of a new era Novel treatments for patients with TKI resistant disease with common EGFR mutations Enriqueta Felip |
| 00:45 EST | Live Q&A: From information to transformation Navigating the evidence with experience sharing in a live forum to improve patient care All |
| Agenda | |
| 00:00 EST | Welcome and Introduction Seng Weng Wong |
| 00:05 EST | Navigating Recent Clinical Data for ALK+ TKIs Thanyanan Reungwetwattana Selecting Treatment and Management of ALK+ NSCLC The Importance of Managing CNS disease The future of ALK+ NSCLC |
| 00:45 EST | Q&A All |
| 00:58 EST | Summary, Thank you and Close Seng Weng Wong |
| Agenda | |
| 00:00 EST | Welcome and Introductions Virginie Westeel, MD, PhD |
| 00:05 EST | What is the role of IO in Non-metastatic NSCLC? Virginie Westeel, MD, PhD |
| 00:20 EST | IO in the treatment of Metastatic NSCLC, where are we now? Julie Brahmer, MD, MSc |
| 00:35 EST | Non-Metastatic and Metastatic NSCLC Q&A Virginie Westeel, MD, PhD Julie Brahmer, MD, MSc |
| 00:40 EST | What is I-O’s impact on the treatment paradigm for Mesothelioma patients? Nicolas Girard, MD |
| 00:55 EST | Mesothelioma Q&A and Closing Remarks Nicolas Girard, MD Virginie Westeel, MD, PhD |
| Agenda | |
| Introductions
Current biomarker landscape in NSCLC Current unmet need in KRAS G12C-mutated NSCLC Emerging novel targets for lung cancer |
| Agenda | |
| 00:00 EST | Introduction David Gandara, MD |
| 00:05 EST | Know How To Test Your Patients John Gosney, MD |
| 00:15 EST | Know How To Sequence EGFR TKIs Barbara Melosky, MD, FRCP(C) |
| 00:25 EST | Know Your Patients With Uncommon EGFR Mutations Satoru Miura, MD, PhD |
| 00:35 EST | What’s Next For Treatment of Advanced Stage Squamous NSCLC David Gandara, MD |
| 00:45 EST | Know What’s Next For Your Patients: Looking to the Future David Gandara, MD |
| 00:55 EST | Closing David Gandara, MD |
| Agenda | |
| 00:00 EST | Welcome, introduction, and interactive quiz Daniel S.W. Tan, MD, PhD |
| 00:05 EST | When is the right time to use NGS-based liquid biopsy in advanced NSCLC? Herbert Ho Fung Loong, MD |
| 00:20 EST | Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice Terufumi Kato, MD |
| 00:35 EST | Enhancing immune checkpoint inhibition with bifunctional antibodies Daniel S.W. Tan, MD, PhD |
| 00:50 EST | Quiz questions revisited and Q&A All |
| 00:59 EST | Pearls for practice Daniel S.W. Tan, MD, PhD |
| Agenda | |
| 00:00 EST | Welcome and introduction Edward Kim |
| 00:05 EST | Presentation: Advances and challenges in EGFR-mutated NSCLC Edward Kim |
| 00:15 EST | Panel discussion: The MDT approach to managing EGFR-mutated NSCLC Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp |
| 00:45 EST | Audience Q&A Faculty and audience |
Date: Sunday, January 31, 2021 | Time: 00:00 - 01:00 EST
| Agenda | |
| 00:00 EST | Opening Remarks Tony Mok |
| 00:03 EST | Biomarker for Lung Cancer: Right Patient, Right Time, Right Test Tony Mok |
| 00:21 EST | Biomarker Panel Testing: PCR panel vs NGS panel Koichi Goto |
| 00:39 EST | Large Scale Real World Study on Rare aActionable Targets in Chinese NSCLC Caicun Zhou |
| 00:57 EST | Closing Remarks Tony Mok |
| Agenda | |
| Welcome, Introduction, Polling Questions
Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC Activity of ADCs in Clinical Trials for Lung Cancer Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC Audience Q&A, Panel Discussion |
| Agenda | |
| 18:30 PST | Opening Remarks Masahiro Tsuboi |
| 18:35 PST | Current Strategies for IO Therapy for Unresectable Stage III NSCLC Glenwood Goss |
| 18:45 PST | Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC Suresh Senan |
| 18:55 PST | Defining the Role of Immunotherapy in the Treatment of ES-SCLC Myung-Ju Ahn |
| 19:05 PST | Emerging Biomarkers in SCLC Charles Rudin |
| 19:15 PST | Panel Discussion / Q&A All |
| Agenda | |
| 19:45 PST | Welcome and Introduction Tony Mok |
| 19:50 PST | Evolving challenges for the treatment of advanced NSCLC Tony Mok |
| 20:00 PST | Emerging ADC targets for the treatment of late-line NSCLC Pasi Jänne |
| 20:15 PST | ADC therapies as targeted treatment options in patients with advanced NSCLC James Yang |
| 20:30 PST | Interactive Q+A/Panel Discussion All |
| Agenda | |
| 21:00 PST | Chair’s Welcome Koichi Goto |
| 21:04 PST | Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC Koichi Goto |
| 21:10 PST | Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC – Practical tips on optimising diagnostic capabilities in the clinic Herbert Loong |
| 21:22 PST | The roles of the Oncologist and Pathologist in providing an actionable diagnosis – Discuss the role of the Tumour Board / MDT in implementing precision medicine Fernando López-Ríos |
| 21:34 PST | Gaining consensus – An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\ Giuseppe Curigliano |
| 21:44 PST | Panel discussion and Q&A All |
| 22:00 PST | Symposium close Koichi Goto |
| Agenda | |
| 22:15 PST | Welcome and Introductions Rina Hui |
| 22:15 PST | Frontline Immunotherapy Treatment Options in mNSCLC Rina Hui |
| 22:30 PST | Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer Roy Herbst |
| 22:45 PST | Choosing Immunotherapy Alone or in Combination in 1L mNSCLC Corey Langer |
| 23:00 PST | Q&A and Closing Remarks Rina Hui |
| Agenda | |
| 23:30 PST | Welcome and introduction Yi-Long Wu |
| 23:30 PST | Evolution of the NSCLC Treatment Landscape Yi-Long Wu |
| 23:40 PST | Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET? Johan F. Vansteenkiste |
| 23:55 PST | Panel discussion All |
| 00:07 PST | Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target Yasushi Goto |
| 00:21 PST | Q&A All |
| 00:29 PST | Closing Yi-Long Wu |
| Agenda | |
| 00:45 PST | The Past, Present and Future of Biomarker-driven Advanced NSCLC Ben Solomon, Shirish Gadgeel, Solange Peters |
| 01:15 PST | Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer Ross Soo, Martin Reck, Solange Peters |
| Agenda | |
| 21:00 PST | Welcome and introductions Tetsuya Mitsudomi |
| 21:05 PST | A light at the end of the tunnel Hope for patients with EGFR Exon20 insertion mutations Byoung Chul Cho |
| 21:25 PST | The dawn of a new era Novel treatments for patients with TKI resistant disease with common EGFR mutations Enriqueta Felip |
| 21:45 PST | Live Q&A: From information to transformation Navigating the evidence with experience sharing in a live forum to improve patient care All |
| Agenda | |
| 21:00 PST | Welcome and Introduction Seng Weng Wong |
| 21:05 PST | Navigating Recent Clinical Data for ALK+ TKIs Thanyanan ReungwetwattanaSelecting Treatment and Management of ALK+ NSCLC Nick Pavlakis The Importance of Managing CNS disease The future of ALK+ NSCLC |
| 21:45 PST | Q&A All |
| 21:58 PST | Summary, Thank you and Close Seng Weng Wong |
| Agenda | |
| 21:00 PST | Welcome and Introductions Virginie Westeel, MD, PhD |
| 21:05 PST | What is the role of IO in Non-metastatic NSCLC? Virginie Westeel, MD, PhD |
| 21:20 PST | IO in the treatment of Metastatic NSCLC, where are we now? Julie Brahmer, MD, MSc |
| 21:35 PST | Non-Metastatic and Metastatic NSCLC Q&A Virginie Westeel, MD, PhD Julie Brahmer, MD, MSc |
| 21:40 PST | What is I-O’s impact on the treatment paradigm for Mesothelioma patients? Nicolas Girard, MD |
| 21:55 PST | Mesothelioma Q&A and Closing Remarks Nicolas Girard, MD Virginie Westeel, MD, PhD |
| Agenda | |
| Introductions
Current biomarker landscape in NSCLC Current unmet need in KRAS G12C-mutated NSCLC Emerging novel targets for lung cancer |
| Agenda | |
| 21:00 PST | Introduction David Gandara, MD |
| 21:05 PST | Know How To Test Your Patients John Gosney, MD |
| 21:15 PST | Know How To Sequence EGFR TKIs Barbara Melosky, MD, FRCP(C) |
| 21:25 PST | Know Your Patients With Uncommon EGFR Mutations Satoru Miura, MD, PhD |
| 21:35 PST | What’s Next For Treatment of Advanced Stage Squamous NSCLC David Gandara, MD |
| 21:45 PST | Know What’s Next For Your Patients: Looking to the Future David Gandara, MD |
| 21:55 PST | Closing David Gandara, MD |
| Agenda | |
| 21:00 PST | Welcome, introduction, and interactive quiz Daniel S.W. Tan, MD, PhD |
| 21:05 PST | When is the right time to use NGS-based liquid biopsy in advanced NSCLC? Herbert Ho Fung Loong, MD |
| 21:20 PST | Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice Terufumi Kato, MD |
| 21:35 PST | Enhancing immune checkpoint inhibition with bifunctional antibodies Daniel S.W. Tan, MD, PhD |
| 21:50 PST | Quiz questions revisited and Q&A All |
| 21:59 PST | Pearls for practice Daniel S.W. Tan, MD, PhD |
| Agenda | |
| 21:00 PST | Welcome and introduction Edward Kim |
| 21:05 PST | Presentation: Advances and challenges in EGFR-mutated NSCLC Edward Kim |
| 21:15 PST | Panel discussion: The MDT approach to managing EGFR-mutated NSCLC Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp |
| 21:45 PST | Audience Q&A Faculty and audience |
Date: Saturday, January 30, 2021 | Time: 21:00 - 22:00 PST
| Agenda | |
| 21:00 PST | Opening Remarks Tony Mok |
| 21:03 PST | Biomarker for Lung Cancer: Right Patient, Right Time, Right Test Tony Mok |
| 21:21 PST | Biomarker Panel Testing: PCR panel vs NGS panel Koichi Goto |
| 21:39 PST | Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC Caicun Zhou |
| 21:57 PST | Closing Remarks Tony Mok |
Should you have any questions regarding the Industry & Satellite CME Symposia, please contact wclc2020-industry at icsevents.com.
Industry Symposia are commercially supported educational and promotional activities held in conjunction with the IASLC 2020 World Conference on Lung Cancer.
The guidelines below pertain to Industry Symposia (IS), which are defined as educational and promotional activities that are not certified for CME.
The Conference Secretariat will liaise on your behalf with the official suppliers and venue. All organizations will be responsible for the management of their own event’s logistics and for payment of costs associated with event promotion, faculty, additional audiovisual equipment, catering and staffing costs. Representatives from the Steering Committee may attend Industry Symposia to audit compliance with these guidelines.
| Deadline to submit Program Draft and Faculty* | July 02, 2020 |
| Deadline to submit Menu, Minimum F&B Guarantee | November 02, 2020 |
| Deadline to submit Artwork for Delegate Bag Insert for Approval | November 02, 2020 |
| Deadline to submit Final Additional AV Requirements | November 02, 2020 |
| Deadline to submit Host/Hostess Order | November 02, 2020 |
| Deadline to submit PDF Sample of Onsite Signage | November 02, 2020 |
| Deadline to submit eBlast Banner Ad | November 02, 2020 |
| Deadline to submit Approved Artwork for Delegate Bag Insert to WCLC 2020 Printer | December 01, 2020 |
| Deadline to submit Final F&B Numbers | December 04, 2020 |
| Deadline to submit Lead Retrieval Order | December 04, 2020 |
| Deadline to submit Additional IS Staff Badges | December 18, 2020 |
| Deadline to submit Full Names for Staff Badges | January 08, 2021 |
| Day 1 | |
|---|---|
| 10:30 - 11:30 SST |
IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by  |
| 11:45 - 12:45 SST |
IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by  |
| 13:00 - 14:00 SST |
IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by  |
| 14:15 - 15:15 SST |
IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by  |
| 15:30 - 16:30 SST |
IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by  |
| 16:45 - 17:45 SST |
IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by  |
| Day 2 | |
| 13:00 - 14:00 SST |
IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by  |
| 13:00 - 14:00 SST |
IS09 - Expert Question Time: ALK+ NSCLC (Not IASLC CME Accredited)
Sponsored by  |
| 13:00 - 14:00 SST |
IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by  |
| Day 3 | |
| 13:00 - 14:00 SST |
IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by  |
| 13:00 - 14:00 SST |
IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by  |
| Day 4 | |
| 13:00 - 14:00 SST |
IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by |
| Day 1 | |
|---|---|
| 03:30 - 04:30 CET |
IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by |
| 04:45 - 05:45 CET |
IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by |
| 06:00 - 07:00 CET |
IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by |
| 07:15 - 08:15 CET |
IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by |
| 08:30 - 09:30 CET |
IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by |
| 09:45 - 10:45 CET |
IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by |
| Day 2 | |
| 06:00 - 07:00 CET |
IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by |
| 06:00 - 07:00 CET |
IS09 - Expert Question Time: ALK+ NSCLC (Not IASLC CME Accredited)
Sponsored by |
| 06:00 - 07:00 CET |
IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by |
| Day 3 | |
| 06:00 - 07:00 CET |
IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by |
| 06:00 - 07:00 CET |
IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by |
| Day 4 | |
| 06:00 - 07:00 CET |
IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by |
| Day 1 | |
|---|---|
| 21:30 - 22:30 EST |
IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by |
| 22:45 - 23:45 EST |
IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by |
| 00:00 - 01:00 EST |
IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by |
| 01:15 - 02:15 EST |
IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by |
| 02:30 - 03:30 EST |
IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by |
| 03:45 - 04:45 EST |
IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by |
| Day 2 | |
| 00:00 - 01:00 EST |
IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by |
| 00:00 - 01:00 EST |
IS09 - Expert Question Time: ALK+ NSCLC (Not IASLC CME Accredited)
Sponsored by |
| 00:00 - 01:00 EST |
IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by |
| Day 3 | |
| 00:00 - 01:00 EST |
IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by |
| 00:00 - 01:00 EST |
IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by |
| Day 4 | |
| 00:00 - 01:00 EST |
IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by |
| Day 1 | |
|---|---|
| 18:30 - 19:30 PST |
IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by |
| 19:45 - 20:45 PST |
IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by |
| 21:00 - 22:00 PST |
IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by |
| 22:15 - 23:15 PST |
IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by |
| 23:30 - 00:30 PST |
IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by |
| 00:45 - 01:45 PST |
IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by |
| Day 2 | |
| 21:00 - 22:00 PST |
IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by |
| 21:00 - 22:00 PST |
IS09 - Expert Question Time: ALK+ NSCLC (Not IASLC CME Accredited)
Sponsored by |
| 21:00 - 22:00 PST |
IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by |
| Day 3 | |
| 21:00 - 22:00 PST |
IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by |
| 21:00 - 22:00 PST |
IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by |
| Day 4 | |
| 21:00 - 22:00 PST |
IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by |
Keep up to date with Conference News & Alerts.
Sign Up
#WCLC20
